Drug Search Results
More Filters [+]

Besifloxacin

Alternative Names: besifloxacin, bol-303224-a, isv-403, isv403, isv 403, besivance
Latest Update: 2023-10-19
Latest Update Note: Clinical Trial Update

Product Description

Besifloxacin ophthalmic is used to treat bacterial conjunctivitis (pinkeye; infection of the membrane that covers the outside of the eyeballs and the inside of the eyelids). Besifloxacin is in a class of medications called fluoroquinolones. It works by killing the bacteria that cause infection. (Sourced from: https://medlineplus.gov/druginfo/meds/a610011.html)

Mechanisms of Action: DNA Gyrase Inhibitor,TOP4 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Ocular,Topical,Ophthalmic

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Bangladesh | Brazil | Canada | Colombia | Egypt | India | Jordan | Lebanon | Malaysia | Mexico | Singapore | South Africa | Taiwan | Thailand | Turkey | United Arab Emirates | United States | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Besifloxacin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events